Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 6/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emidurdar SCHEMBL30845296 | 1.00 | KCNMA1 (0.54) | KCNMA1GRIK1TMPRSS4GPR35TRPV1 | |
| SCHEMBL4718263 | 0.92 | GPR35 (0.47) | KCNMA1GRIK1GPR35TRPV1MAPT | |
| SCHEMBL1462393 | 0.91 | GRIK1 (0.60) | KCNMA1GRIK1GPR35TRPV1MAPT | |
| SCHEMBL2834395 | 0.88 | KCNMA1 (0.69) | KCNMA1TMPRSS4GPR35MAPTKDR | |
| SCHEMBL1463472 | 0.87 | GRIK1 (0.47) | KCNMA1GRIK1TMPRSS4TRPV1MAPT | |
| SCHEMBL3579491 | 0.86 | PSEN1 (0.47) | KCNMA1TRPV1MAPTKDRCA12 | |
| SCHEMBL1463507 | 0.85 | KMT2A (0.45) | GRIK1MAPTCA12CA1CA2 | |
| SCHEMBL3580763 | 0.85 | PSEN1 (0.45) | KCNMA1GRIK1TMPRSS4TRPV1MAPT | |
| SCHEMBL1463403 | 0.84 | KDR (0.45) | GRIK1MAPTKDRCA12CA1 | |
| SCHEMBL3574142 | 0.84 | PSEN1 (0.44) | KCNMA1GRIK1TMPRSS4TRPV1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663192-B1 | hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NEUROSEARCH AS (DK) | 2008-12-03 | — | — | EP | claimed |
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | NEUROSEARCH A/S (DK) | 2007-12-20 | — | — | US | claimed |
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2006-12-14 | — | — | US | claimed |
| EP-1663192-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | Poseidon Pharmaceuticals A/S (DK) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023237-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | claimed |
| WO-2005023238-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | claimed |
| US-20240360087-A1 | THERMODYNAMICALLY STABLE FORM OF SCO-101 | SCANDION ONCOLOGY A/S (DK) | 2024-10-31 | — | — | US | disclosed |
| EP-4182303-B1 | THERMODYNAMICALLY STABLE FORM OF SCO-101 | SCANDION ONCOLOGY AS (DK) | 2023-11-29 | — | — | EP | disclosed |
| EP-4182303-B1 | THERMODYNAMICALLY STABLE FORM OF SCO-101 | SCANDION ONCOLOGY AS (DK) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023285344-A1 | THERMODYNAMICALLY STABLE FORM OF SCO-101 | SCANDION ONCOLOGY A/S (DK) | 2023-01-19 | — | — | WO | disclosed |
| US-20210251963-A1 | UREA DERIVATIVES FOR USE IN THE TREATMENT OF SUBJECTS WITH ELEVATED EXPRESSION AND/OR ACTIVITY OF SRPK1 | SCANDION ONCOLOGY A/S (DK) | 2021-08-19 | — | — | US | disclosed |
| US-20110071164-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | OLESEN SOEREN PETER | 2011-03-24 | — | — | US | disclosed |
| US-7851492-B2 | ERG channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| EP-1663192-B1 | hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NEUROSEARCH AS (DK) | 2008-12-03 | — | — | EP | disclosed |
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | NEUROSEARCH A/S (DK) | 2007-12-20 | — | — | US | disclosed |
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2006-12-14 | — | — | US | disclosed |
| EP-1663192-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | Poseidon Pharmaceuticals A/S (DK) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023238-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023237-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | disclosed |
| WO-2004012733-A9 | COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES RESPONSIVE TO ANTIANGIOGENETIC THERAPY | NEUROSEARCH AS (DK) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | KCNJ2, KCNN3, KCNE1 | KCNMA1 76/4885GRIK1 622/4885TMPRSS4 795/4885 |
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | KCNJ2, KCNH2, KCNH3 | KCNMA1 43/4885GRIK1 216/4885TMPRSS4 734/4885 |
| US-20110071164-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | KCNJ2, KCNN3, KCNE1 | KCNMA1 76/4885GRIK1 622/4885TMPRSS4 795/4885 |
| US-20210251963-A1 | UREA DERIVATIVES FOR USE IN THE TREATMENT OF SUBJECTS WITH ELEVATED EXPRESSION AND/OR ACTIVITY OF SRPK1 | SRPK1, SRPK3, HNRNPK | KCNMA1 4141/4885GRIK1 2667/4885TMPRSS4 2974/4885 |
| US-20240360087-A1 | THERMODYNAMICALLY STABLE FORM OF SCO-101 | SCO2, SFXN1, IPO11 | KCNMA1 2235/4885GRIK1 4202/4885TMPRSS4 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.